The median OS reported in clinical trials in the first-line setting with gefitinib (for EGFR-mutated adenocarcinoma) was 18.6 months [6], and with alectinib (for ALK-rearranged adenocarcinoma), it was not reached after close to 50 months of follow-up [7,8]. This evidence concerns the gene EGFR and adenocarcinoma.